Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: A comparison with clinically used tumor markers

Clinical Cancer Research

Volumn 6, Issue 6, 2000, Pages 2333-2340

  Sier, Cornelis F M ^a   Casetta, Giovanni ^b   Verheijen, Jan H ^c   Tizzani, Alessandro ^b   Agape, Vittorio ^a   Kos, Janko ^d   Blasi, Francesco ^a   Hanemaaijer, Roeland ^c  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b Institute of Nephro Urology   (Italy)

^c TNO   (Netherlands)

^d JO EF STEFAN INSTITUTE   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GROWTH; CANCER STAGING; CELL MIGRATION; CORRELATION FUNCTION; DIAGNOSTIC VALUE; ENZYME ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CASE-CONTROL STUDIES; CATHEPSIN B; CREATININE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM INVASIVENESS; NUCLEAR PROTEINS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0034122601     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Stein, J. P., Grossfeld, G. D., Ginsberg, D. A., Esrig, D., Freeman, J. A., Figueroa, A. J., Skinner, D. G., and Cote, R. J. Prognostic markers in bladder cancer: a contemporary review of the literature. J. Urol., 160: 645-659, 1998.
2. Messing, E. M., and Murphy-Brooks, N. Recovery of epidermal growth factor in voided urine of patients with bladder cancer. Urology, 44: 502-506, 1994.
3. Casetta, G., Piana, P., Cavallini, A., Vottero, M., and Tizzani, A. Urinary levels of tumour associated antigens (CA 19-9, TPA and CEA) in patients with neoplastic and non-neoplastic urothelial abnormalities. Br. J. Urol., 72: 60-64, 1993.
4. Schmetter, B. S., Habicht, K. K., Lamm, D. L., Morales, A., Bander, N. H., Grossman, H. B., Hanna, M. G., Silberman, S. R., and Butman, B. T. A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer. J. Urol., 158: 801-805, 1997.
5. Sarosdy, M. F., DeVere White, R. W., Soloway, M. S., Sheinfeld, J., Hudson, M. A., Schellhammer, P. F., Jarowenko, M. V., Adams, G., and Blumenstein, B. A. results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J. Urol., 154: 379-384, 1995.
6. Soloway, M. S., Briggman, J. V., Carpinito, G. A., Chodak, G. W., Church, P. A., Lamm, D. L., Lange, P., Messing, E., Pasciak, R. M., Reservitz, G. B., Rukstalis, D. B., Sarosdy, M. F., Stadler, W. M., Thiel, R. P., and Hayden, C. L. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J. Urol., 156: 363-367, 1996.
7. Margulies, I. M., Hoyhtya, M., Evans, C., Stracke M. L., Liotta, L. A., and Stetler-Stevenson, W. G. Urinary type IV collagenase: elevated levels are associated with bladder transitional carcinoma. Cancer Epidemiol. Biomark. Prev., 1: 467-474, 1992.
8. Moses, M. A., Wiederschain, D., Loughlin, K. R., Zurakowski, D., Lamb, C. C., and Freeman, M. R. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res., 58: 1395-1399, 1998.
9. Nutt, J. E., Mellon, J. K., Qureshi, K., and Lunec, J. Matrix metalloproteinase-1 is induced by epidermal growth factor in human bladder tumour cell lines and is detectable in urine of patients with bladder tumours. Br. J. Cancer, 78: 215-220, 1998.
10. Bianco, F. J., Gervasi, D. C., Tiguert, R., Grignon, D. J., Pontes, J. E., Crissman, J. D., Fridman, R., and Wood, D. P. Matrix metalloproteinase-9 expression in bladder washes from bladder cancer patients predict pathological stage and grade. Clin. Cancer Res., 4: 3011-3016, 1998.
11. Birkedal-Hansen, H., Moore, W., Bodden, M., Windsor, L., Birkedal-Hansen, B., Decarlo, A., and Engler, J. Matrix-metalloproteinases: a review. Crit. Rev. Oral Biol. Med., 4: 197-250, 1993.
12. Liotta, L. A., Steeg, P. S., and Stetler-Stevenson, W. G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 64: 327-336, 1991.
13. Chambers, A. F., and Matrisian, L. M. Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst., 89: 1260-1270, 1998.
14. Murray, G., Duncan, M., O'Neil, P., Melvin, W., and Fothergill, J. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat. Med., 2: 461-462, 1996.
15. Sier, C. F. M., Kubben, F. J. G. M., Ganesh, S., Heerding, M. M., Griffioen, G., Hanemaaijer, R., Van Krieken, J. H. J. M., Lamers, C. B. H. W., and Verspaget H. W. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br. J. Cancer, 74: 413-417, 1996.
16. r 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res., 55: 140-146, 1993.
17. Baker, T., Tickle, S., Wasan, H., Docherty, A., Isenberg, D., and Waxman, J. Serum metalloproteinases and their inhibitors: markers for malignant potential. Br. J. Cancer, 70: 506-512, 1994.
18. Torii, A., Kodera, Y., Uesaka, K., Hirai, T., Yasui, K., Morimoto, T., Yamamura, Y., Kato, T., Hayakawa, T., Fujimoto, N., and Kito, T. Plasma concentration of matrix metalloproteinase 9 in gastric cancer. Brit. J. Surg., 84: 133-136, 1997.
19. Gohji, K., Fujimoto, N., Hara, I., Fujii, A., Gotoh, A., Okada, H., Arakawa, S., Kitazawa, S., Miyake, H., Kamidono, S., and Nakajima, M. Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. Int. J. Cancer (Pred. Oncol.), 79: 96-101, 1998.
20. Iizasa, T., Fujisawa, T., Suzuki, M., Motohashi, S., Yasufuku, K., Yasukawa, T., Baba, M., and Shiba, M. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients. Clin. Cancer Res., 5: 149-153, 1999.
21. Ozdemir, E., Kakehi, Y., Okuno H., and Yoshida, O. Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas. J. Urol., 161: 1359-1363, 1999.
22. Verheijen, J. H., Nieuwenbroek, N., Beekman, B., Hanemaaijer, R., Verspaget, H. W., Ronday, H., and Bakker, A. Modified proenzymes as artificial substrates for proteolytic enzymes: colorimetric assay of bacterial collagenase and matrix metalloproteinase activity using modified pro-urokinase. Biochem. J., 323: 603-609, 1997.
23. Hanemaaijer, R., Visser, H., Konttinen, Y., Koolwijk, P., and Verheijen, J. H. A novel and simple immunocapture assay for determination of gelatinase-B (MMP-9) activities in biological fluids: saliva from patients with Sjögren's syndrome contain increased latent and active gelatinase-B levels. Matrix Biol., 17: 657-665, 1998.
24. Union Internationale Contre le Cancer (UICC). P. Hermanek and L. H. Sobin (eds.). TNM Classification of Malignant Tumours, Ed. 4, pp. 133-135. Berlin, Heidelberg, New York, London, Paris, and Tokyo: Springer-Verlag, 1987.
25. Hanemaaijer, R., Koolwijk, P., Le Clercq, L., De Vree, W., and Van Hinsbergh, V. Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells - effects of tumour necrosis factor-α, interleukin-1 and phorbol ester. Biochem. J., 296: 803-809, 1993.
26. Koolwijk, P., Van Erck, M. G. M., De Vree, W. J. A., Vermeer, M. A., Weich, H. A., Hanemaaijer, R., and Van Hinsbergh, V. W. M. Cooperative effect of TNFα, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity. J. Cell Biol., 132: 1177-1188, 1996.
27. Kos, J., Stabuc, B., Schweiger, A., Krasovec, M., Cimerman, N., Kopitar-Jerala, N., and Vrhovec, I. Cathepsins B, H, L, and their inhibitors stefin Am and cystatin C in sera of melanoma patients. Clin. Cancer Res., 3: 1815-1822, 1997.
28. Kos, J., Nielsen, H. J., Krasovec, M, Christensen, I. J., Cimerman, N., Stephens, R. W., and Brünner, N. Prognostic values of cathepsin B and carcinoembryonic antigen in sera of patients with colorectal cancer. Clin. Cancer Res., 4: 1511-1516, 1998.
29. Verspaget, H. W., Kubben, F. J. G. M., Tschesche, H., Verheijen, J. H., Hanemaaijer, R., Lamers, C. B. H. W. Matrix metalloproteinases increase with colorectal cancer progression. Fibrinol. Proteol., 13 (Suppl 1): 38, 1999.
30. Davies, B., Waxman, J., Wasan, H., Abel, P., Williams, G., Krausz, T., Neal, D., Thomas, D., Hanby, A., and Balkwill, F. Levels of matrix metalloproteinases in bladder cancer correlate with tumor grade and invasion. Cancer Res., 53: 5365-5369, 1993.
31. Leber, T. M., and Balkwill, F. R. Regulation of monocyte MMP-9 production by TNF-α and a tumour-derived soluble factor (MMPSF). Br. J. Cancer, 78: 724-732, 1998.